STREAMEX CORP. (STEX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.71M USD | Liabilities, Current |
| Cash and equivalents | 5.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 12.86M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.71M | $5.61M | $12.86M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $3.30M | $6.86M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $42.79M | $20.30M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $125.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $113.20M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.68M | (m) | (m) | $109.00K | (m) | (m) |
| 2024-12-31 | (m) | $2.26M | (m) | (m) | $109.00K | (m) | (m) |
| 2024-09-30 | (m) | $1.70M | (m) | (m) | $81.00K | (m) | (m) |
| 2024-06-30 | (m) | $2.98M | (m) | (m) | $54.00K | (m) | (m) |
| 2024-03-31 | (m) | $5.23M | (m) | (m) | $14.00K | (m) | (m) |
| 2023-12-31 | (m) | $4.58M | $200.00K | (m) | $24.00K | (m) | (m) |
| 2023-09-30 | (m) | $3.91M | $400.00K | (m) | $14.00K | $219.00K | (m) |
| 2023-06-30 | (m) | $3.33M | $1.30M | (m) | $21.00K | $189.00K | (m) |
| 2023-03-31 | (m) | $2.81M | $1.40M | (m) | $17.00K | $345.00K | (m) |
| 2022-12-31 | (m) | $3.26M | $400.00K | (m) | $9.00K | $336.00K | (m) |
| 2022-09-30 | (m) | $2.54M | $900.00K | (m) | $5.00K | $1.69M | (m) |
| 2022-06-30 | (m) | $1.90M | $5.10M | (m) | (m) | $2.03M | (m) |
| 2022-03-31 | (m) | $2.71M | $8.70M | (m) | (m) | $2.03M | (m) |
| 2021-12-31 | (m) | $2.58M | $11.70M | (m) | (m) | $1.88M | (m) |
| 2021-09-30 | (m) | $2.57M | $17.54M | (m) | $100.00K | $1.88M | (m) |
| 2021-06-30 | (m) | $3.38M | $15.50M | (m) | $199.00K | $731.05K | (m) |
| 2021-03-31 | (m) | $3.90M | $22.48M | (m) | (m) | $649.94K | (m) |
| 2020-12-31 | (m) | $5.11M | $28.27M | (m) | (m) | $768.32K | (m) |
| 2020-09-30 | (m) | $4.96M | $32.75M | (m) | (m) | $806.41K | (m) |
| 2020-06-30 | (m) | $3.61M | $36.93M | (m) | (m) | $800.00K | (m) |
| 2020-03-31 | (m) | $1.58M | $15.50M | (m) | (m) | $800.00K | (m) |
| 2019-12-31 | (m) | $2.03M | $12.11M | (m) | (m) | $577.69K | (m) |
| 2019-09-30 | (m) | $1.21M | $12.31M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.41M | $10.33M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.01M | $10.93M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.20M | $4.45M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $720.36K | $7.28M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $525.23K | $3.67M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $821.45K | $1.04M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.97M | $1.55M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $4.22M | $234.28K | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $4.27M | $880.66K | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.57M | $1.24M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.96M | $1.06M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $3.38M | $150.45K | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $3.22M | $705.34K | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.76M | $137.61K | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.47M | $953.23K | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $2.72M | $334.56K | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $5.69M | $1.20M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $6.76M | $2.06M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.23M | $239.78K | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $837.14K | $268.88K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $883.44K | $42.19K | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $5.37K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $3.02M | $302.19K | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $65.48K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $304.94K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $24.24K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B |